A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
Conditions : Healthy Participants; Participants With Moderate Renal Impairment Interventions : Drug: ammoxetine hydrochloride enteric-coated tablets Sponsors : CSPC ZhongQi Pharmaceutical Technology…
Read the full article16h agoen
You might also wanna read
Untitled
Telitacicept, a fusion protein targeting BAFF and APRIL, shows promise for IgA nephropathy in a phase 3 trial. Proteinuria ≥1.0 g/day addres
doi.org·23d ago
AstraZeneca compra a una farmacéutica de China los derechos de un medicamento pulmonar por 1.900 millones
Se trata de un inhibidor dual de PDE3/4 concebido para proporcionar efectos broncodilatadores y antiinflamatorios simultáneos.
20MINUTOS.ES·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.